Microspheres as pulmonary delivery systems - A review

doi:10.5246/jcps.2021.07.043

Abstract

Abstract:

Microspheres are one of the delivery systems, which can be used to protect drugs or proteins especially for pulmonary purposes since these particles can be a direct target to the lung and their mucoadhesive properties. Their advantages could help cure pulmonary diseases. There are several methods of polymers to form microspheres depending on the physicochemical characteristics of polymers. In this review, we aimed to discuss methods to produce microspheres from conventional to advanced techniques, and various polymers that can be designed to form microspheres, and aerosolization properties of the inhalable particles for pulmonary delivery were discussed. With this comprehensive review, our findings will enhance pharmaceutical knowledge, promote wide uses of microspheres, and produce new techniques to prepare inhalable pulmonary microspheres.

Key words: Microspheres, Pulmonary diseases, Delivery

Supporting:

Dewi Melani Hariyadi, Esti Hendradi, Herlina Eka Pratama, Mahardian Rahmadi. Microspheres as pulmonary delivery systems - A review[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(7): 545-555.

Figures/Tables 2

References 38

[1]	Santiwarangkool, S.; Akita, H.; Khalil, I.A.; Abd Elwakil, M.M.; Sato, Y.; Kusumoto, K.; Harashima, H. A study of the endocytosis mechanism and transendothelial activity of lung-targeted GALA-modified liposomes.J. Control. Release. 2019, 307, 55–63.
[2]	Saigal, A.; Ng, W.K.; Tan, R.B.H.; Chan, S.Y. Development of controlled release inhalable polymeric microspheres for treatment of pulmonary hypertension. Int. J. Pharm. 2013, 450, 114–122.
[3]	Feng, T.S.; Tian, H.Y.; Xu, C.N.; Lin, L.; Xie, Z.G.; Lam, M.H.W.; Liang, H.J.; Chen, X.S. Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment. Eur. J. Pharm. Biopharm. 2014, 88, 1086–1093.
[4]	Grenha, A.; Remuñán-López, C.; Carvalho, E.L.S.; Seijo, B. Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. Eur. J. Pharm. Biopharm. 2008, 69, 83–93.
[5]	Yang, T.T.; Wen, B.F.; Liu, K.; Qin, M.; Gao, Y.Y.; Ding, D.J.; Li, W.T.; Zhang, Y.X.; Zhang, W.F. Cyclosporine A/porous quaternized chitosan microspheres as a novel pulmonary drug delivery system. Artif. Cells Nanomed. Biotechnol. 2018, 46, 552–564.
[6]	Hirota, K.; Hasegawa, T.; Nakajima, T.; Inagawa, H.; Kohchi, C.; Soma, G.I.; Makino, K.; Terada, H. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J. Control. Release. 2010, 142, 339–346.
[7]	Manconi, M.; Manca, M.L.; Valenti, D.; Escribano, E.; Hillaireau, H.; Fadda, A.M.; Fattal, E. Chitosan and hyaluronan coated liposomes for pulmonary administration of curcumin. Int. J. Pharm. 2017, 525, 203–210.
[8]	Gidwani, B.; Vyas, A. A comprehensive review on cyclodextrin-based carriers for delivery of chemotherapeutic cytotoxic anticancer drugs. Biomed. Res. Int. 2015, 2015, 198268.
[9]	Gaspar, M.C.; Sousa, J.J.S.; Pais, A.A.C.C.; Cardoso, O.; Murtinho, D.; Serra, M.E.S.; Tewes, F.; Olivier, J.C. Optimization of levofloxacin-loaded crosslinked chitosan microspheres for inhaled aerosol therapy. Eur. J. Pharm. Biopharm. 2015, 96, 65–75.
[10]	Park, J.H.; Jin, H.E.; Kim, D.D.; Chung, S.J.; Shim, W.S.; Shim, C.K. Chitosan microspheres as an alveolar macrophage delivery system of ofloxacin via pulmonary inhalation. Int. J. Pharm. 2013, 441, 562–569.
[11]	Saraogi, G.K.; Gupta, P.; Gupta, U.D.; Jain, N.K.; Agrawal, G.P. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int. J. Pharm. 2010, 385, 143–149.
[12]	Yamada, K.; Kamada, N.; Odomi, M.; Okada, N.; Nabe, T.; Fujita, T.; Kohno, S.; Yamamoto, A. Carrageenans can regulate the pulmonary absorption of antiasthmatic drugs and their retention in the rat lung tissues without any membrane damage. Int. J. Pharm. 2005, 293, 63–72.
[13]	Athamneh, T.; Amin, A.; Benke, E.; Ambrus, R.; Leopold, C.S.; Gurikov, P.; Smirnova, I. Alginate and hybrid alginate-hyaluronic acid aerogel microspheres as potential carrier for pulmonary drug delivery. J. Supercrit. Fluids. 2019, 150, 49–55.
[14]	Diab, R.; Brillault, J.; Bardy, A.; Gontijo, A.V.L.; Olivier, J.C. Formulation and in vitro characterization of inhalable polyvinyl alcohol-free rifampicin-loaded PLGA microspheres prepared with sucrose palmitate as stabilizer: Efficiency for ex vivo alveolar macrophage targeting. Int. J. Pharm. 2012, 436, 833–839.
[15]	Doan, T.V.P.; Couet, W.; Olivier, J.C. Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery. Int. J. Pharm. 2011, 414, 112–117.
[16]	Ohashi, K.; Kabasawa, T.; Ozeki, T.; Okada, H. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J. Control. Release. 2009, 135, 19–24.
[17]	Rawat, A.; Majumder, Q.H.; Ahsan, F. Inhalable large porous microspheres of low molecular weight heparin: In vitro and in vivo evaluation. J. Control. Release. 2008, 128, 224–232.
[18]	Silva, D.M.; Paleco, R.; Traini, D.; Sencadas, V. Development of ciprofloxacin-loaded poly(vinyl alcohol) dry powder formulations for lung delivery. Int. J. Pharm. 2018, 547, 114–121.
[19]	Gaspar, M.C.; Pais, A.A.C.C.; Sousa, J.J.S.; Brillaut, J.; Olivier, J.C. Development of levofloxacin-loaded PLGA microspheres of suitable properties for sustained pulmonary release. Int. J. Pharm. 2019, 556, 117–124.
[20]	Kapoor, D.N.; Bhatia, A.; Kaur, R.; Sharma, R.; Kaur, G.; Dhawan, S. PLGA: a unique polymer for drug delivery. Ther. Deliv. 2015, 6, 41–58.
[21]	Huang, H.; Wang, Y.X.; Jiang, C.G.; Lang, L.W.; Wang, H.Y.; Chen, Y.; Zhao, Y.; Xu, Z.J. Intrapulmonary concentration of levofloxacin in patients with idiopathic pulmonary fibrosis. Pulm. Pharmacol. Ther. 2014, 28, 49–52.
[22]	Govender, T.; Stolnik, S.; Garnett, M.C.; Illum, L.; Davis, S.S. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J. Control. Release. 1999, 57, 171–185.
[23]	Disratthakit, A.; Doi, N.; Takenaga, M.; Ohta, Y. Anti-tuberculosis activity and drug interaction with nevirapine of inhalable lipid microspheres containing rifampicin in murine model. J. Microencapsul. 2010, 27, 365–371.
[24]	Mura, S.; Hillaireau, H.; Nicolas, J.; Kerdine-Römer, S.; Le Droumaguet, B.; Deloménie, C.; Nicolas, V.; Pallardy, M.; Tsapis, N.; Fattal, E. Biodegradable nanoparticles meet the bronchial airway barrier: how surface properties affect their interaction with mucus and epithelial cells. Biomacromolecules. 2011, 12, 4136–4143.
[25]	Bianco, I.D.; Balsinde, J.; Beltramo, D.M.; Castagna, L.F.; Landa, C.A.; Dennis, E.A. Chitosan-induced phospholipase A2 activation and arachidonic acid mobilization in P388D1 macrophages. FEBS Lett. 2000, 466, 292–294.
[26]	Ventura, C.A.; Tommasini, S.; Crupi, E.; Giannone, I.; Cardile, V.; Musumeci, T.; Puglisi, G. Chitosan microspheres for intrapulmonary administration of moxifloxacin: Interaction with biomembrane models and in vitro permeation studies. Eur. J. Pharm. Biopharm. 2008, 68, 235–244.
[27]	Giovagnoli, S.; Blasi, P.; Schoubben, A.; Rossi, C.; Ricci, M. Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery. Int. J. Pharm. 2007, 333, 103–111.
[28]	Sakagami, M.; Kinoshita, W.; Sakon, K.; Sato, J.I.; Makino, Y. Mucoadhesive beclomethasone microspheres for powder inhalation: their pharmacokinetics and pharmacodynamics evaluation. J. Control. Release. 2002, 80, 207–218.
[29]	Rodrigues, S.; Cordeiro, C.; Seijo, B.; Remuñán-López, C.; Grenha, A. Hybrid nanosystems based on natural polymers as protein carriers for respiratory delivery: Stability and toxicological evaluation. Carbohydr. Polym. 2015, 123, 369–380.
[30]	Varshosaz, J.; Taymouri, S.; Hamishehkar, H. Fabrication of polymeric nanoparticles of poly(ethylene-co-vinyl acetate) coated with chitosan for pulmonary delivery of carvedilol. J. Appl. Polym. Sci. 2014, 131, 39694.
[31]	Du, P.; Du, J.; Smyth, H.D.C. Evaluation of granulated lactose as a carrier for dry powder inhaler formulations 2: effect of drugs and drug loading. J. Pharm. Sci. 2017, 106, 366–376.
[32]	Feng, R.H.; Zhang, Z.Y.; Li, Z.W.; Huang, G.H. Preparation and in vitro evaluation of etoposide-loaded PLGA microspheres for pulmonary drug delivery. Drug Deliv. 2014, 21, 185–192.
[33]	Wanakule, P.; Liu, G.W.; Fleury, A.T.; Roy, K. Nano-inside-micro: Disease-responsive microgels with encapsulated nanoparticles for intracellular drug delivery to the deep lung. J. Control. Release. 2012, 162, 429–437.
[34]	Kolesnyk, I.; National University of Kiev Mohyla Academy Skovoroda str Kiev Ukraine, Konovalova, V.; Burban, A.; National University of Kiev Mohyla Academy Skovoroda str Kiev Ukraine, National University of Kiev Mohyla Academy Skovoroda str Kiev Ukraine. Alginate/κ-carrageenan microspheres and their application for protein drugs controlled release. Chem. Chem. Technol. 2015, 9, 485–492.
[35]	Hwang, S.M.; Kim, D.D.; Chung, S.J.; Shim, C.K. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis. J. Control. Release. 2008, 129, 100–106.
[36]	Sah, E.; Sah, H. Recent trends in preparation of poly(lactide-co-glycolide) nanoparticles by mixing polymeric organic solution with antisolvent. J. Nanomater. 2015, 2015, 1–22.
[37]	Luinstra, M.; Grasmeijer, F.; Hagedoorn, P.; Moes, J.R.; Frijlink, H.W.; de Boer, A.H. A levodopa dry powder inhaler for the treatment of Parkinson's disease patients in off periods. Eur. J. Pharm. Biopharm. 2015, 97, 22–29.
[38]	Lakio, S.; Morton, D.A.V.; Ralph, A.P.; Lambert, P. Optimizing aerosolization of a high-dose L-arginine powder for pulmonary delivery. Asian J. Pharm. Sci. 2015, 10, 528–540.